Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478.

Authors

Xiao Liu, Yanyan Chen, Guanyi Li, Anqi Chen, Qingtong Zhou, Ming-Wei Wang

Published in

Acta pharmaceutica Sinica. B. Volume 16. Issue 9. Pages 5884-5900. Epub Jul 05, 2026.

Abstract

Hotspot mutations in phosphoinositide 3-kinase alpha (PI3Kα), such as H1047R, E542K, and E545K, drive tumorigenesis across multiple cancer types. Orthosteric PI3Kα inhibitors are effective but have toxicity against wild-type PI3Kα, the emergence of resistance, and a narrow therapeutic index. Allosteric inhibitors such as RLY-2608 and STX-478 offer a promising path toward mutant-specific suppression, yet the structural basis for their selectivity and mechanisms of action remain elusive. Here, we report high-resolution cryogenic electron microscopy structures of RLY-2608- and STX-478-bound H1047R, E542K, and E545K, revealing a shared cryptic allosteric pocket, accessible only through a major conformational rearrangement of the activation loop that is stabilized in oncogenic mutants. While both inhibitors occupy this pocket, they have distinct interaction networks and propagate divergent allosteric activities: RLY-2608 induces large-scale remodeling of catalytic and membrane-interacting elements, whereas STX-478 reinforces autoinhibitory interfaces between p110α and p85α subunits. Comparative analysis provides structural insights into their differentiated potency and selectivity.

PMID:
42764855
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.